JF
SMMT icon

Jump Financial’s Summit Therapeutics SMMT Stock Holding History

Jump Financial’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.68M Buy
389,618
+273,880
+237% +$4.86M 0.05% 471
2026
Q1 		$2.19M Buy
+115,738
New +$1.87M 0.03% 619
2025
Q3 		– Sell
-11,452
Closed -$244K – 2200
2025
Q2 		$244K Buy
+11,452
New +$261K ﹤0.01% 1521
2024
Q2 		– Sell
-22,462
Closed -$93K – 2220
2024
Q1 		$93K Buy
+22,462
New +$89.3K ﹤0.01% 1799
2023
Q2 		– Sell
-11,859
Closed -$20.8K – 2130
2023
Q1 		$20.8K Buy
+11,859
New +$32.3K ﹤0.01% 1508

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jump Financial's SMMT Position: Q2 2026 in Review

Jump Financial increased its Summit Therapeutics (SMMT) stake by 237% in Q2 2026, buying an estimated $4.86M and bringing the position to 389,618 shares worth $5.68M. The position accounts for 0.05% of the portfolio, ranked #471.

Jump Financial first reported a position in SMMT in Q1 2023 and has held it in 5 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Jump Financial held 389,618 shares of Summit Therapeutics worth $5.68M as of Q2 2026.
  • Jump Financial bought 273,880 Summit Therapeutics shares in Q2 2026, an estimated $4.86M.
  • Summit Therapeutics made up 0.05% of Jump Financial's portfolio in Q2 2026, its #471 holding.
  • Jump Financial first reported a position in Summit Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.